文献速递类风湿关节炎

类风湿关节炎临床试验中的全球招募模式与安慰剂反应

Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2025-08-05

该研究分析124项靶向治疗类风湿关节炎的随机对照试验(14 272例患者),以人均国民总收入为社会经济代理指标,发现人均国民总收入与安慰剂反应率呈负相关(每增加10 000国际元,安慰剂反应率降低3.7%,95%CI:-5.61至-1.80,P<.001),而活性治疗反应保持稳定。

要点

  • 人均国民总收入每增加10 000国际元,安慰剂反应率降低3.7%(95%CI:-5.61至-1.80,P<.001)。
  • 从低收入国家招募患者与较高的安慰剂反应率相关,而活性治疗反应保持稳定。
  • 作者认为,这一关联可能由招募患者的激励因素驱动,如欠富裕国家治疗可及性有限。

核心结论

  • 从低收入国家招募患者与较高的安慰剂反应率相关,而活性治疗反应保持稳定。
  • 作者认为,这一关联可能由招募患者的激励因素驱动,如欠富裕国家治疗可及性有限。
  • 作者指出,解决这些因素对于改进试验设计和确保准确的疗效评估至关重要。

研究设计与样本

  • 分析了124项研究靶向治疗的类风湿关节炎随机对照试验,共14 272例患者。
  • 使用线性混合模型评估全球招募模式与安慰剂反应率的关系,以人均国民总收入(按招募中心/国家加权)作为社会经济地位的代理指标。
  • 主要结局为美国风湿病学会20%缓解标准(ACR20)的安慰剂反应率。
  • 其他社会经济指标包括人类发展指数和自付医疗支出。
  • 使用一项全球随机对照试验的患者层面数据验证结果。

主要发现

  • 在所有试验中,人均国民总收入与安慰剂反应率呈负相关(β=-3.7%安慰剂反应/每10 000国际元;95%CI:-5.61至-1.80;P<.001)。
  • 使用替代指标以及个体患者层面的地理数据验证了结果。
  • 与活性治疗反应相比,该关联存在有意义的差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Placebo effects pose significant challenges in clinical trials for rheumatoid arthritis (RA). Understanding how socioeconomic factors of recruiting countries influence placebo responses is crucial for improving clinical trial design and outcomes. Here, we investigated the impact of global recruitment patterns on placebo responses in randomised controlled trials of RA. METHODS: We analysed 124 trials (14 272 patients) investigating targeted therapeutics in RA and assessed how global recruitment patterns are related to placebo response rates using the per-capita gross national income (GNI; weighted by recruiting centres/country) as proxy for socioeconomic status in linear mixed models. Primary outcome was the American College of Rheumatology 20% response placebo response rate. Other socioeconomic metrics utilised were the Human Development Index and out-of-pocket health expenditures. Findings were validated using patient-level data from one global in randomised controlled trial. RESULTS: We identified a negative association of GNI and placebo response rates across all trials (β = -3.7% placebo response per 10 000 international dollars; 95% CI: -5.61 to -1.80; P < .001). Results were confirmed using alternative metrics as well as using geographic data on individual patient level. Importantly, we could demonstrate a meaningful difference of this association when compared to active treatment responses. CONCLUSIONS: Our findings indicate that recruiting patients from lower-income countries is associated with higher placebo response rates, whereas active treatment responses remain stable. This may be driven by incentives to recruit patients into trials, such as limited access to therapies in less affluent countries. Addressing these factors is critical for improving trial design and ensuring accurate efficacy assessments.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kerschbaumer A, Steiner M, Pruckner P, et al. Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis. Ann Rheum Dis. 2025. PMID: 40752975. doi:10.1016/j.ard.2025.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。